Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

13.64
-0.3400-2.43%
Post-market: 13.640.00000.00%19:30 EDT
Volume:108.64K
Turnover:1.48M
Market Cap:233.32M
PE:-3.54
High:13.95
Open:13.87
Low:13.51
Close:13.98
52wk High:16.77
52wk Low:11.13
Shares:17.11M
Float Shares:15.72M
Volume Ratio:0.69
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8578
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:1.09
PE(LYR):-4.28

Loading ...

Company Profile

Company Name:
Atrium Therapeutics
Exchange:
NASDAQ
Establishment Date:
2025
Employees:
- -
Office Location:
10578 Science Center Drive,Suite 125,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.